Skip to content

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Bertrand Coiffier, Éric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Réda Bouabdallah, Pierre Morel, Éric Van Den Neste, Gilles Andre Salles, Philippe Gaulard, Félix Reyes, Pierre Lederlin, Christian Gisselbrecht

New England Journal of Medicine · 2002 · 5,644 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Coiffier, B., Lepage, É., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Neste, É. V. D., Salles, G. A., Gaulard, P., Reyes, F., Lederlin, P., & Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse Large-B-Cell lymphoma. New England Journal of Medicine, 346(4), 235–242. https://doi.org/10.1056/nejmoa011795

In text: (Coiffier et al., 2002)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. METHODS: Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients). RESULTS: The rate of complete response was significantly higher in the group that received CHOP plus rituximab than in the group that received CHOP alone (76 percent vs. 63 percent, P=0.005). With a median follow-up of two years, event-free and overall survival times were significantly higher in the CHOP-plus-rituximab group (P<0.001 and P=0.007, respectively). The addition of rituximab to standard CHOP chemotherapy significantly reduced the risk of treatment failure and death (risk ratios, 0.58 [95 percent confidence interval, 0.44 to 0.77] and 0.64 [0.45 to 0.89], respectively). Clinically relevant toxicity was not significantly greater with CHOP plus rituximab. CONCLUSIONS: The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.

  1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms2016
  2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017
  3. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014
  4. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia2002
  5. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma1993

Metadata from OpenAlex (CC0). Citations are generated from the published record.